Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johannes Duell

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Haematologica|July 1, 2021
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphomaJohannes Duell, Kami J Maddocks, Eva González-Barca, et al.
The Lancet. Haematology|April 3, 2022
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trialRajat Bannerji, Jon E Arnason, Ranjana H Advani, et al.
British Journal of Haematology|May 8, 2024
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker studyXiang Zhou, Vivien Wagner, Lukas Scheller, et al.
Blood|August 22, 2024
Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myelomaMara John, Moutaz Helal, Johannes Duell, et al.
The Lancet. Haematology|June 12, 2026
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trialUmberto Vitolo, Juan Miguel Bergua Burgues, Johannes Duell, et al.
Nature Medicine|February 23, 2021
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myelomaMatteo C Da Vià, Oliver Dietrich, Marietta Truger, et al.
Lancet (London, England)|May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialGeorg Lenz, Marek Trněný, John M Burke, et al.
Blood Cancer Journal|July 30, 2025
Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvementMaximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, et al.
Blood Cancer Discovery|March 26, 2026
Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel TherapySofie-Katrin Kadel, Lukas Scheller, Alexander M Leipold, et al.
Blood Advances|July 1, 2021
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomasNora Liebers, Johannes Duell, Donnacha Fitzgerald, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Haematologica|July 1, 2021
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphomaJohannes Duell, Kami J Maddocks, Eva González-Barca, et al.
The Lancet. Haematology|April 3, 2022
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trialRajat Bannerji, Jon E Arnason, Ranjana H Advani, et al.
British Journal of Haematology|May 8, 2024
Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker studyXiang Zhou, Vivien Wagner, Lukas Scheller, et al.
Blood|August 22, 2024
Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myelomaMara John, Moutaz Helal, Johannes Duell, et al.
The Lancet. Haematology|June 12, 2026
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trialUmberto Vitolo, Juan Miguel Bergua Burgues, Johannes Duell, et al.
Nature Medicine|February 23, 2021
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myelomaMatteo C Da Vià, Oliver Dietrich, Marietta Truger, et al.
Lancet (London, England)|May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialGeorg Lenz, Marek Trněný, John M Burke, et al.
Blood Cancer Journal|July 30, 2025
Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvementMaximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, et al.
Blood Cancer Discovery|March 26, 2026
Multiomic and Longitudinal Dissection of Immune Dynamics Associated with Parkinsonism after Ciltacabtagene Autoleucel TherapySofie-Katrin Kadel, Lukas Scheller, Alexander M Leipold, et al.
Blood Advances|July 1, 2021
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomasNora Liebers, Johannes Duell, Donnacha Fitzgerald, et al.
Pageof 5